Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.68 |
| ▸ | MAOB | P27338 | 8/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.48 |
| ▸ | RELA | Q04206 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | LPL | P06858 | 2/20 | 0.46 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15331009 | 0.89 | ENPP2 (0.74) | ENPP2MAOBTP53PKMNFKB1 | |
| SCHEMBL2556339 | 0.88 | ENPP2 (0.60) | ENPP2MAOBLPLLIPG | |
| SCHEMBL2555065 | 0.86 | ENPP2 (0.71) | ENPP2MAOBTP53PKMNFKB1 | |
| SCHEMBL16687432 | 0.86 | ENPP2 (0.59) | ENPP2MAOBFFAR1LPLLIPG | |
| SCHEMBL30688670 | 0.85 | ENPP2 (0.65) | ENPP2MAOBFFAR1TP53PKM | |
| SCHEMBL29138052 | 0.85 | ENPP2 (0.65) | ENPP2MAOBFFAR1TP53PKM | |
| SCHEMBL2558160 | 0.85 | ENPP2 (0.61) | ENPP2MAOBTP53PKMNFKB1 | |
| SCHEMBL177403 | 0.84 | MAOB (0.62) | ENPP2MAOBFFAR1 | |
| SCHEMBL2561245 | 0.84 | ENPP2 (0.64) | ENPP2MAOBRAB9ASMN1; SMN2MRGPRX4 | |
| SCHEMBL29952469 | 0.84 | MAOB (0.62) | ENPP2MAOBRAB9AF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2015-11-05 | — | — | US | disclosed |
| US-9024071-B2 | Therapeutic compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | ENPP2 147/4885MAOB 780/4885FFAR1 1083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.